TCL Archive Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial January 27, 2012
TCL Archive In Brief: NCAB Will Consider Holding “Circuit Rider” Meetings; Kaplan Asked to Speak On Hybridomas May 1, 1981